Peng Zhong, Zhong Shuzhu, Li Xinyun, Yu Fengyi, Tang Zixu, Ma Chunyuan, Liao Zihao, Zhao Song, Xia Yuan, Fu Haojun, Long Wei, Lei Mingxing, He Zhangxiu
Department of Nephrology, Yiyang Central Hospital, 118 Kangfubei Road, Yiyang, Hunan, 413000, People's Republic of China.
Department of Gastroenterology, Yiyang Central Hospital, Yiyang, Hunan, China.
Sci Rep. 2025 Jul 29;15(1):27699. doi: 10.1038/s41598-025-06576-8.
Hemodialysis stands as the most prevalent renal replacement therapy globally. Accurately identifying mortality among hemodialysis patients is paramount importance, as it enables the formulation of tailored interventions and facilitates timely management. The objective of the study was to establish and validate an artificial intelligence (AI) model to predict mortality among hemodialysis patients. The data of 559 patients with hemodialysis at a large tertiary hospital were retrospectively analyzed, and those of 82 patients were extracted from another tertiary hospital. The patients from the large tertiary hospital constituted the model development cohort, and the patients from another tertiary hospital constituted the external validation cohort. The patients in the model development cohort were randomly divided into a training cohort and an internal validation cohort at a ratio of 8:2. The machine learning algorithms used to develop the models for the training group included logistic regression (LR), decision tree (DT), extreme gradient boosting machine (eXGBM), neural network (NN), and support vector machine (SVM). The predictive performances of all the models were evaluated using discrimination and calibration. In addition, a comprehensive scoring system to evaluate the prediction performance of the model was also used, the scoring system had the scores ranging from 0 to 50. The optimal model had the highest total score for the internal and external validation, and was further deployed as an AI application using Streamlit. The rates of mortality at one year, four years, and seven years in the model development group were determined to be 2.68%, 15.38%, and 33.09%, respectively. The model, which predicted mortality at these time points, achieved impressive area under the curve (AUC) values of 0.979 (95% CI: 0.959-0.998), 0.933 (95% CI: 0.916-0.958), and 0.935 (95% CI: 0.895-0.976), respectively, using the eXGBM model. The corresponding accuracies were 0.931, 0.889, and 0.931, with precision values of 0.891, 0.857, and 0.891, and brier scores of 0.051, 0.096, and 0.051, respectively. Notably, the eXGBM model outperformed other models with a score of 46 in the comprehensive scoring system, followed by the NN model with a score of 35. External validation further confirmed the robust predictive performance of the eXGBM model, with an AUC value of 0.892 (95% CI: 0.840-0.945). The eXGBM model emerged as the most reliable predictor of mortality among hemodialysis patients in this study. This model has been made available online at https://mortality-among-hemodialysis-bpypyb4dxvq4hja29kwsev.streamlit.app/ . Users can simply access the link, input relevant features, and receive predictions on mortality risk. Furthermore, the AI model provides insights into how the predictions were generated and offers personalized recommendations for intervention strategies. This study has successfully developed and validated an AI application for assessing mortality risk in hemodialysis patients. This tool empowers healthcare professionals to promptly identify individuals at high risk of mortality, thereby aiding in clinical decision-making and intervention planning. For patients at high risk of early death, caution is advised when considering kidney transplant surgery. Conversely, for those with a high probability of extended survival, kidney transplant surgery may present a favorable treatment option.
血液透析是全球最普遍的肾脏替代疗法。准确识别血液透析患者的死亡率至关重要,因为这有助于制定针对性的干预措施并促进及时管理。本研究的目的是建立并验证一个人工智能(AI)模型,以预测血液透析患者的死亡率。对一家大型三级医院的559例血液透析患者的数据进行了回顾性分析,并从另一家三级医院提取了82例患者的数据。来自大型三级医院的患者构成模型开发队列,来自另一家三级医院的患者构成外部验证队列。模型开发队列中的患者按8:2的比例随机分为训练队列和内部验证队列。用于为训练组开发模型的机器学习算法包括逻辑回归(LR)、决策树(DT)、极端梯度提升机(eXGBM)、神经网络(NN)和支持向量机(SVM)。使用区分度和校准来评估所有模型的预测性能。此外,还使用了一个综合评分系统来评估模型的预测性能,该评分系统的分数范围为0至50分。最优模型在内部和外部验证中的总分最高,并使用Streamlit进一步部署为AI应用程序。模型开发组中1年、4年和7年的死亡率分别确定为2.68%、15.38%和33.09%。使用eXGBM模型预测这些时间点死亡率的模型,其曲线下面积(AUC)值分别达到了令人印象深刻的0.979(95%置信区间:0.959 - 0.998)、0.933(95%置信区间:0.916 - 0.958)和0.935(95%置信区间:0.895 - 0.976)。相应的准确率分别为0.931、0.889和0.931,精确率值分别为0.891、0.857和0.891,布里尔分数分别为0.051、0.096和0.051。值得注意的是,在综合评分系统中,eXGBM模型以46分的成绩优于其他模型,其次是得分为35分的NN模型。外部验证进一步证实了eXGBM模型强大的预测性能,其AUC值为0.892(95%置信区间:0.840 - 0.945)。在本研究中,eXGBM模型成为血液透析患者死亡率最可靠的预测指标。该模型已在https://mortality-among-hemodialysis-bpypyb4dxvq4hja29kwsev.streamlit.app/ 上线。用户只需访问该链接,输入相关特征,即可获得死亡率风险预测。此外,AI模型还能深入了解预测是如何生成的,并提供个性化的干预策略建议。本研究成功开发并验证了一个用于评估血液透析患者死亡风险的AI应用程序。该工具使医疗保健专业人员能够迅速识别出高死亡风险个体,从而有助于临床决策和干预计划。对于早期死亡风险高的患者,在考虑肾脏移植手术时应谨慎。相反,对于生存时间可能延长的患者,肾脏移植手术可能是一个有利的治疗选择。